Mergers and Acquisitions

Katana Biopharma in its acquisition by Theratechnologies

Katana Biopharma Inc.
Key Contact
Nathalie Beauregard

Partner, Emerging and High Growth Companies, Montréal

Team
Alain Fournier

Partner, Tax, Montréal

On February 25, 2019, Theratechnologies acquired Katana Biopharma and its targeted oncology technology platform for $8.1 million. The acquisition is part of the companies’ long-term growth strategy to utilize Katana’s platform to continue development and execute their marketing strategies.

Katana Biopharma is a Montreal based biotech company that engages in the development of targeted oncology drugs.

Theratechnologies Inc., based out of Montreal, is a specialty pharmaceutical company, that addresses medical needs of HIV patients to promote healthy living and improve quality of life.

Osler, Hoskin & Harcourt LLP represented Katana Biopharma with a team led by Nathalie Beauregard (Corporate) that included Alain Fournier (Tax).

Value
$8.1 million
Date Closed
February 25, 2019
Lead Office
Montréal
Key Contact
Nathalie Beauregard

Partner, Emerging and High Growth Companies, Montréal

Team
Alain Fournier

Partner, Tax, Montréal